Utang agregat perusahaan: tharimmune.com (THAR)

Tharimmune, Inc. specializes in the discovery of anti-tumor agents, fully outsourcing drug synthesis to third-party CMOs. Total debt reflects liability trends, with the value stabilizing at 0.00, as the firm delegates clinical trials to external contractors to maintain flexibility. However, the lack of revenue and the requirement for antibody laboratories make scaling the pipeline a costly process.

Stress testing assets requires an analysis of liability dynamics to identify systemic default risks and assess capital resilience to external shocks. For Tharimmune, Inc. (THAR), which develops unique anti-inflammatory biologics, the total debt volume reflects R&D financing costs, allowing investors to distinguish temporary borrowings from a critical increase in debt load amid the development of niche medications.